{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:40Z","timestamp":1791264520365,"version":"4.1.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","europeanneuropsychopharmacology.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.euroneuro.2015.07.010","type":"journal-article","created":{"date-parts":[[2015,7,21]],"date-time":"2015-07-21T16:15:25Z","timestamp":1437495325000},"page":"1556-1565","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase"],"prefix":"10.1016","volume":"25","author":[{"given":"Fran\u00e7ois","family":"Montastruc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5660-9224","authenticated-orcid":false,"given":"Aurore","family":"Palmaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haleh","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre-Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.euroneuro.2015.07.010_bib1","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s10147-009-0912-5","article-title":"Receptor occupancy theory-based analysis of interindividual differences in antiemetic effects of 5-HT3 receptor antagonists","volume":"14","author":"Ayuhara","year":"2009","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib2","series-title":"Martindale: The Complete Drug Reference","author":"Brayfield","year":"2014"},{"key":"10.1016\/j.euroneuro.2015.07.010_bib3","series-title":"Goodman and Gilman\u05f3s the Pharmacological Basis of Therapeutics","author":"Brunton","year":"2011"},{"issue":"12","key":"10.1016\/j.euroneuro.2015.07.010_bib4","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.4088\/JCP.v63n1208","article-title":"The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis","volume":"63","author":"Caro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.euroneuro.2015.07.010_bib5","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0022-3565(25)39283-9","article-title":"5-HT1A and alpha-2 adrenergic receptors mediate the hyperglycemic and hypoinsulinemic effects of 8-hydroxy-2-(di-N-propylamino)tetralin in the conscious rat","volume":"243","author":"Chaouloff","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.euroneuro.2015.07.010_bib6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1176\/appi.ps.55.9.1006","article-title":"Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients","volume":"55","author":"Citrome","year":"2004","journal-title":"Psychiatr. Serv."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.07.010_bib7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.pharmthera.2010.04.008","article-title":"Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design","volume":"127","author":"Coccurello","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.euroneuro.2015.07.010_bib71","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death","volume":"26","author":"De Bruin","year":"2005","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib8","doi-asserted-by":"crossref","unstructured":"Expert Group \u2018Schizophrenia and Diabetes 2003\u2019 Expert Consensus Meeting, 2004, Dublin, 3\u20134 October 2003: consensus summary, Br. J. Psychiatry 184 (Suppl. 47), S112-S114.","DOI":"10.1192\/bjp.184.47.s112"},{"key":"10.1016\/j.euroneuro.2015.07.010_bib9","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1136\/bmj.321.7273.1371","article-title":"Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis","volume":"321","author":"Geddes","year":"2000","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib10","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/01.psy.0000174994.91245.34","article-title":"Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics","volume":"67","author":"Gilles","year":"2005","journal-title":"Psychosom. Med."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.07.010_bib11","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/jnc.12213","article-title":"Brain-derived neurotrophic factor, corticotropin-releasing factor, and hypothalamic neuronal histamine interact to regulate feeding behavior","volume":"125","author":"Gotoh","year":"2013","journal-title":"J. Neurochem."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2015.07.010_bib12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2015.07.010_bib13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0031-1286287","article-title":"AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011","volume":"44","author":"Hiemke","year":"2011","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.euroneuro.2015.07.010_bib14","unstructured":"iPHACE,2015. Available from: \u3008http:\/\/agave.health.unm.edu\/iphace\/main.php?text=fluoxetine&source=all\u3009. (accessed 2015)."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib15","unstructured":"IUPHAR \u2013 International Union of Basic and Clinical Pharmacology, 2015. Available from: \u3008http:\/\/www.iuphar.org\/\u3009. (accessed 2015)."},{"issue":"5\u20136","key":"10.1016\/j.euroneuro.2015.07.010_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1159\/000095339","article-title":"Increased susceptibility to diet-induced obesity in histamine-deficient mice","volume":"83","author":"J\u00f8rgensen","year":"2006","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.euroneuro.2015.07.010_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/YPG.0000000000000053","article-title":"Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia","volume":"24","author":"Kang","year":"2014","journal-title":"Psychiatr. Genet."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.07.010_bib18","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2015.07.010_bib19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.tips.2004.02.012","article-title":"Principles: receptor theory in pharmacology","volume":"25","author":"Kenakin","year":"2004","journal-title":"Trends Pharmacol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2015.07.010_bib20","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-8993(98)00186-3","article-title":"Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats","volume":"793","author":"Lecklin","year":"1998","journal-title":"Brain Res."},{"issue":"7584","key":"10.1016\/j.euroneuro.2015.07.010_bib21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/bmj.39090.484074.DB","article-title":"Drug company seeks to suppress internal memos","volume":"334","author":"Lenzer","year":"2007","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/009286150804200501","article-title":"VigiBase, the WHO global ICSR database system: basic facts","volume":"42","author":"Lindquist","year":"2008","journal-title":"Drug Inform. J."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib23","first-page":"1180","article-title":"The WHO programme for international drug monitoring, its database, and the technical support of the uppsala monitoring center","volume":"28","author":"Lindquist","year":"2001","journal-title":"J. Rheumatol."},{"issue":"7151","key":"10.1016\/j.euroneuro.2015.07.010_bib24","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/bmj.317.7151.119","article-title":"Underreporting of suspected adverse drug reactions to newly marketed (\u201cblack triangle\u201d) drugs in general practice: observational study","volume":"317","author":"Martin","year":"1998","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.euroneuro.2015.07.010_bib25","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.2337\/diabetes.53.9.2250","article-title":"Involvement of hypothalamic histamine H1 receptor in the regulation of feeding rhythm and obesity","volume":"53","author":"Masaki","year":"2004","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib26","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.euroneuro.2015.07.010_bib27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s002130000639","article-title":"Insulin and leptin levels in patients with schizophrenia or related psychoses\u2014a comparison between different antipsychotic agents","volume":"154","author":"Melkersson","year":"2001","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2015.07.010_bib28","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.schres.2007.12.487","article-title":"Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1","volume":"101","author":"Meyer","year":"2008","journal-title":"Schizophr. Res."},{"issue":"6","key":"10.1016\/j.euroneuro.2015.07.010_bib29","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"6","key":"10.1016\/j.euroneuro.2015.07.010_bib30","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":"Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods","volume":"73","author":"Montastruc","year":"2006","journal-title":"Joint Bone Spine: Rev. Du Rhum."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib31","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0031-9384(99)00123-7","article-title":"Involvement of the histaminergic system in leptin-induced suppression of food intake","volume":"67","author":"Morimoto","year":"1999","journal-title":"Physiol. Behav."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.07.010_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JCP.0b013e3181934462","article-title":"HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study","volume":"29","author":"Mulder","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.07.010_bib33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol. Psychiatry"},{"issue":"4","key":"10.1016\/j.euroneuro.2015.07.010_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"issue":"7","key":"10.1016\/j.euroneuro.2015.07.010_bib35","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1185\/03007995.2013.794776","article-title":"Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity","volume":"29","author":"Nigro","year":"2013","journal-title":"Curr. Med. Res. Opin."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.07.010_bib36","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/2647","article-title":"Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene","volume":"4","author":"Nonogaki","year":"1998","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.07.010_bib37","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/BF03261981","article-title":"Effect of competition bias in safety signal generation: analysis of a research database of spontaneous reports in France","volume":"35","author":"Pariente","year":"2012","journal-title":"Drug Saf.: Int. J. Med. Toxicol. Drug Exp."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.07.010_bib38","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib39","unstructured":"\u00ab PDSP \u2013 Home Page, 2015. Available from: \u3008http:\/\/pdsp.med.unc.edu\/indexR.html\u3009. (accessed 2015)."},{"issue":"4","key":"10.1016\/j.euroneuro.2015.07.010_bib40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1124\/mol.107.038083","article-title":"Serotonin 5-hydroxytryptamine2C receptor signaling in hypothalamic proopiomelanocortin neurons: role in energy homeostasis in females","volume":"72","author":"Qiu","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib41","doi-asserted-by":"crossref","unstructured":"Rang H.P., Dale M.M., Ritter J.M., Flower R.J., Henderson G., 2012. Rang & Dale\u05f3s Pharmacology. 7th ed.","DOI":"10.1016\/B978-0-7020-3471-8.00001-9"},{"issue":"1","key":"10.1016\/j.euroneuro.2015.07.010_bib42","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment\u2014pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.07.010_bib43","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/tpj.2010.66","article-title":"Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study","volume":"12","author":"Risselada","year":"2012","journal-title":"Pharmacogenomics J."},{"issue":"8","key":"10.1016\/j.euroneuro.2015.07.010_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0447.2008.01158.x","article-title":"Diabetes and Schizophrenia \u2013 effect of disease or drug? results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia","volume":"117","author":"Saddichha","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"issue":"1\u20132","key":"10.1016\/j.euroneuro.2015.07.010_bib46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0006-8993(90)90373-J","article-title":"Hypothalamic Neuronal histamine modulates ad libitum feeding by rats","volume":"537","author":"Sakata","year":"1990","journal-title":"Brain Res."},{"issue":"7","key":"10.1016\/j.euroneuro.2015.07.010_bib47","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40264-013-0063-5","article-title":"A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France","volume":"36","author":"Salvo","year":"2013","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre","year":"2005","journal-title":"Methods Find. Exp. Clin. Pharmacol."},{"issue":"10","key":"10.1016\/j.euroneuro.2015.07.010_bib49","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1007\/s12272-010-1018-3","article-title":"The regulation of blood glucose level in physical and emotional stress models: possible involvement of adrenergic and glucocorticoid systems","volume":"33","author":"Sim","year":"2010","journal-title":"Arch. Pharmacal Res."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.07.010_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1600-0447.2008.01334.x","article-title":"Which comes first: atypical antipsychotic treatment or cardiometabolic risk?","volume":"119","author":"Stahl","year":"2009","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib51","series-title":"Stahl\u05f3s Essential Psychopharmacology","author":"Stahl","year":"2013"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib52","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2165\/11587540-000000000-00000","article-title":"Suspected adverse drug reactions reported for children worldwide: an exploratory study using VigiBase","volume":"34","author":"Star","year":"2011","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.07.010_bib53","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause diabetes mellitus? insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur. Psychiatry: J. Assoc. Eur. Psychiatr."},{"key":"10.1016\/j.euroneuro.2015.07.010_bib54","series-title":"Pharmacoepidemiology","author":"Strom","year":"2012"},{"key":"10.1016\/j.euroneuro.2015.07.010_bib55","unstructured":"\u00ab The Uppsala Monitoring Centre \u2013 VigiBaseTM, 2015. Consult\u00e9 le f\u00e9vrier 16. \u3008http:\/\/www.umc-products.com\/DynPage.aspx?id=73590&mn1=1107&mn2=1132\u3009."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.07.010_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2009.01425.x","article-title":"Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies","volume":"121","author":"Verdoux","year":"2010","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.euroneuro.2015.07.010_bib57","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1210\/en.2007-0927","article-title":"Synergistic impairment of glucose homeostasis in Ob\/ob mice lacking functional serotonin 2C receptors","volume":"149","author":"Wade","year":"2008","journal-title":"Endocrinology"},{"key":"10.1016\/j.euroneuro.2015.07.010_bib58","unstructured":"\u00ab WHO | WHO Regional Offices, 2015. WHO. Available from: \u3008http:\/\/www.who.int\/about\/regions\/en\/\u3009. (accessed 2015)."},{"issue":"1","key":"10.1016\/j.euroneuro.2015.07.010_bib59","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/syn.10111","article-title":"Prediction and assessment of extrapyramidal side effects induced by risperidone based on dopamine D(2) receptor occupancy","volume":"46","author":"Yamada","year":"2002","journal-title":"Synapse"},{"issue":"5","key":"10.1016\/j.euroneuro.2015.07.010_bib60","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmet.2007.10.008","article-title":"Serotonin 2C Receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways","volume":"6","author":"Zhou","year":"2007","journal-title":"Cell Metab."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1500228X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X1500228X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T10:34:49Z","timestamp":1748514889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X1500228X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0924977X1500228X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.07.010","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2015.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}